Takeda Pharmaceutical Company Limited

Tokyo Medical and Dental University

Takeda Pharmaceutical Company Limied

Institute of Science Tokyo

Takatoshi Yogo

Hideki Furukawa

Tomohiro Seki

Tetsuya Nagata

Masaki Seto

Masato Yoshida

Takanori Yokota

Shigekazu Sasaki

Kosuke Hidaka

Yasuo Nakagawa

Ryosuke Tokunoh

Kenichi Miyata

Hiroyuki Nagamiya

Masato Yoshikawa

Satoshi Sasaki

Hideo Suzuki

Tsuneo Oda

Norihito Tokunaga

Minoru Sasaki

Kazuyoshi Aso

Tomokazu Kusumoto

Morihisa Saitoh

Shogo Marui

Yuji Ishichi

Yoshihisa Nakada

Hyun Bin Kang

Kousuke Hidaka

Yusuke Ohba

Toshiki Murata

Hye Sun Jeon

Cheolhwan Yoon

Taisuke Katoh

Kyoko Toyofuku

Yusuke Adachi

Chul Yun Rhim

Akio Uchida

Kwang Ok Kim

Gil Nam Lee

Naoto Arimura

The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted Calkyl group, a substituted or unsubstituted Calkenyl group, or a substituted or unsubstituted Calkoxy group.

BBB-crossing lipid ligand of hetero nucleic acid

Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Nucleic acid complex

The present invention provides a heterocyclic compound having an RIP1 kinase inhibitory action, which is useful for the prophylaxis or treatment of Gaucher's disease, Niemann-Pick disease, inflammatory bowel disease, multiple sclerosis, chronic kidney disease, acute kidney injury, acute hepatic failure, autoimmune hepatitis, hepatitis B, hepatitis C, alcohol steatohepatitis, non-alcohol steatohepatitis and the like. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.

Aromatic ring compound

Growing community of inventors

Kanagawa, Japan

Takatoshi Yogo